|
1
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, et al: Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim
JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: A
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okamoto I, Yoshioka H, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naïve patients with advanced
non-small-cell lung cancer: Results of a west Japan oncology group
study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawahara M, Furuse K, Segawa Y, Yoshimori
K, Matsui K, Kudoh S, Hasegawa K and Niitani H: Phase II study of
S-1, a novel oral fluorouracil, in advanced non-small-cell lung
cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Urata Y, Okamoto I, Takeda M, Hattori Y,
Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, et
al: Phase 2 study of S-1 and carboplatin plus bevacizumab followed
by maintenance S-1 and bevacizumab for chemotherapy-naive patients
with advanced nonsquamous non-small cell lung cancer. Cancer.
119:2275–2281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Wang R, Pan Y, Sun Y, Zhang J and
Chen H: The pemetrexed-containing treatments in the non-small cell
lung cancer is -/low thymidylate synthase expression better than +/
high thymidylate synthase expression: A meta-analysis. BMC Cancer.
14:2052014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB, et al: Colorectal tumors responding to 5-fluorouracil
have low gene expression levels of dihydropyrimidine dehydrogenase,
thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.PubMed/NCBI
|
|
9
|
Metzger R, Danenberg K, Leichman CG,
Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L
and Danenberg PV: High basal level gene expression of thymidine
phosphorylase (platelet-derived endothelial cell growth factor) in
colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clin Cancer Res. 4:2371–2376. 1998.PubMed/NCBI
|
|
10
|
Saito S, Tsuno N, Nagawa H, Sunami E,
Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T:
Expression of platelet-derived endothelial cell growth factor
correlates with good prognosis in patients with colorectal
carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonanomi A, Kojic D, Giger B, Rickenbach
Z, Jean-Richard-Dit-Bressel L, Berger C, Niggli FK and Nadal D:
Quantitative cytokine gene expression in human tonsils at excision
and during histoculture assessed by standardized and calibrated
real-time PCR and novel data processing. J Immunol Methods.
283:27–43. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pérez S, Royo LJ, Astudillo A, Escudero D,
Alvarez F, Rodríguez A, Gómez E and Otero J: Identifying the most
suitable endogenous control for determining gene expression in
hearts from organ donors. BMC Mol Biol. 8:1142007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T))method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kobayashi H, Tanisaka K, Doi O, Kodama K,
Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, et
al: An in vitro chemosensitivity test for solid human tumors using
collagen gel droplet embedded cultures. Int J Oncol. 11:449–455.
1997.PubMed/NCBI
|
|
15
|
Kobayashi H, Higashiyama M, Minamigawa K,
Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination
of in vitro chemosensitivity test using collagen gel droplet
culture method with colorimetric endpoint quantification. Jpn J
Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Higashiyama M, Kodama K, Yokouchi H,
Takami K, Nakagawa H, Imamura F, Minamigawa K and Kobayashi H:
Cisplatin-based chemotherapy for postoperative recurrence in
non-small cell lung cancer patients: Relation of the in vitro
chemosensitive test to clinical response. Oncol Rep. 8:279–283.
2001.PubMed/NCBI
|
|
17
|
The Japan Lung Cancer Society, . General
rule for clinical and pathological record of lung cancer. 7th.
Kanehara & Co., Ltd.; Tokyo: 2010
|
|
18
|
Liu Q, Yu Z, Xiang Y, Wu N, Wu L, Xu B,
Wang L, Yang P, Li Y and Bai L: Prognostic and predictive
significance of thymidylate synthase protein expression in
non-small cell lung cancer: A systematic review and meta-analysis.
Cancer Biomark. 15:65–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang T, Pan C Chuan, Rui Yu J, Long Y, Cai
X Hong, De Yin X, Hao L Qiong and Li Luo L: Association between
TYMS expression and efficacy of pemetrexed-based chemotherapy in
advanced non-small cell lung cancer: A meta-analysis. PLoS One.
8:e742842013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ibe T, Shimizu K, Nakano T, Kakegawa S,
Kamiyoshihara M, Nakajima T, Kaira K and Takeyoshi I: High-grade
neuroendocrine carcinoma of the lung shows increased thymidylate
synthase expression compared to other histotypes. J Surg Oncol.
102:11–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sasako M, Terashima M, Ichikawa W, Ochiai
A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T and Imamura
H: Impact of the expression of thymidylate synthase and
dihydropyrimidine dehydrogenase genes on survival in stage II/III
gastric cancer. Gastric Cancer. 18:538–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou J, Lambers M, den Hamer B, den Bakker
MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J and Philipsen S:
Expression profiling-based subtyping identifies novel non-small
cell lung cancer subgroups and implicates putative resistance to
pemetrexed therapy. J Thorac Oncol. 7:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monica V, Scagliotti GV, Ceppi P, Righi L,
Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S and
Papotti M: Differential thymidylate synthase expression in
different variants of large-cell carcinoma of the lung. Clin Cancer
Res. 15:7547–7552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sowers R, Toguchida J, Qin J, Meyers PA,
Healey JH, Huvos A, Banerjee D, Bertino JR and Gorlick R: mRNA
expression levels of E2F transcription factors correlate with
dihydrofolate reductase, reduced folate carrier, and thymidylate
synthase mRNA expression in osteosarcoma. Mol Cancer Ther.
2:535–541. 2003.PubMed/NCBI
|
|
25
|
Igawa S, Ryuge S, Wada M, Otani S, Maki S,
Takakura A, Katono K, Sasaki J, Sato Y and Masuda N: Pemetrexed for
previously treated patients with non-small cell lung cancer and
differences in efficacy according to thymidylate synthase
expression. Chemotherapy. 58:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takezawa K, Okamoto I, Okamoto W, Takeda
M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K and
Nakagawa K: Thymidylate synthase as a determinant of pemetrexed
sensitivity in non-small cell lung cancer. Br J Cancer.
104:1594–1601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nicolson MC, Fennell DA, Ferry D, O'Byrne
K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, et
al: Thymidylate synthase expression and outcome of patients
receiving pemetrexed for advanced nonsquamous non-small-cell lung
cancer in a prospective blinded assessment phase II clinical trial.
J Thorac Oncol. 8:930–939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren DN, Kim IY, Koh SB, Chang SJ, Eom M,
Yi SY, Seong SH, Kim MD, Bronner MP and Cho MY: Comparative
analysis of thymidylate synthase at the protein, mRNA, and DNA
levels as prognostic markers in colorectal adenocarcinoma. J Surg
Oncol. 100:546–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka F, Wada H, Fukui Y and Fukushima M:
Thymidylate synthase (TS) gene expression in primary lung cancer
patients: A large-scale study in Japanese population. Ann Oncol.
22:1791–1797. 2011. View Article : Google Scholar : PubMed/NCBI
|
